Cutia Therapeutics (HK:2487)
:2487
Want to see HK:2487 full AI Analyst Report?
2487 Stock Chart & Stats
HK$4.59
-HK$0.09(-1.60%)
At close: 4:00 PM EST
HK$4.59
-HK$0.09(-1.60%)
Day’s Range― - ―
52-Week RangeHK$2.91 - HK$12.00
Previous CloseN/A
Volume1.53M
Average Volume (3M)399.60K
Market Cap
HK$1.17B
Enterprise ValueHK$1.02B
Total Cash (Recent Filing)HK$789.16M
Total Debt (Recent Filing)HK$317.53M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding364,730,870
10 Day Avg. Volume272,590
30 Day Avg. Volume399,603
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.45Price Target Upside62.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$588.44M
Bulls Say, Bears Say
Bulls Say
Revenue Growth AccelerationA sustained acceleration to +30.8% revenue growth indicates expanding commercial traction and product adoption. Over a 2–6 month horizon this trend supports operating leverage, increases market penetration, and shortens the horizon to scale fixed costs toward break-even as revenue expands.
Healthy Gross MarginA gross margin near 46% implies strong unit economics and pricing power relative to peers. Structurally, healthy gross margins provide a durable buffer to fund R&D and SG&A, improving the odds that profitability can emerge once operating expenses stabilize and revenue growth continues.
Manageable Leverage And Equity CushionModerate leverage (D/E ~0.36) and a sizable equity base give the company structural financial flexibility. This reduces immediate refinancing pressure, preserves optionality for R&D investment, and allows continued operation while pursuing a path to profitability or executing strategic initiatives.
Bears Say
Sustained Negative Cash FlowLarge negative operating and free cash flows are a structural constraint: continued external financing will be required until cash generation flips. This elevates dilution risk, limits strategic flexibility, and makes the business dependent on capital markets rather than internally generated funds.
Deep Operating And Net LossesVery large operating and net losses indicate the company remains in heavy investment mode and far from profitability. Persistently negative margins weaken resilience to shocks, extend the timeline to sustainable earnings, and raise the probability of needing repeated capital raises before positive cash flow.
Eroding Equity And Negative ROENegative ROE and falling equity reflect shareholder-capital erosion from consecutive losses. Structurally this can increase borrowing costs, constrain strategic options, and signal weakening capital efficiency unless profitability or capital injections reverse the trend over the medium term.
Cutia Therapeutics News
2487 FAQ
What was Cutia Therapeutics’s price range in the past 12 months?
Cutia Therapeutics lowest stock price was HK$2.91 and its highest was HK$12.00 in the past 12 months.
What is Cutia Therapeutics’s market cap?
Cutia Therapeutics’s market cap is HK$1.17B.
When is Cutia Therapeutics’s upcoming earnings report date?
Cutia Therapeutics’s upcoming earnings report date is Aug 27, 2026 which is in 67 days.
How were Cutia Therapeutics’s earnings last quarter?
Cutia Therapeutics released its earnings results on Mar 24, 2026. The company reported -HK$0.304 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.304.
Is Cutia Therapeutics overvalued?
According to Wall Street analysts Cutia Therapeutics’s price is currently Undervalued.
Does Cutia Therapeutics pay dividends?
Cutia Therapeutics does not currently pay dividends.
What is Cutia Therapeutics’s EPS estimate?
Cutia Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cutia Therapeutics have?
Cutia Therapeutics has 364,730,870 shares outstanding.
What happened to Cutia Therapeutics’s price movement after its last earnings report?
Cutia Therapeutics reported an EPS of -HK$0.304 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.951%.
Which hedge fund is a major shareholder of Cutia Therapeutics?
Currently, no hedge funds are holding shares in HK:2487
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cutia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.34%
12-Months-Change
Fundamentals
Return on Equity
-41.43%
Trailing 12-Months
Asset Growth
-1.87%
Trailing 12-Months
Company Description
Cutia Therapeutics
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
2487 Stock 12 Month Forecast
Average Price Target
HK$7.45
▲(62.31% Upside)
Technical Analysis
JW (Cayman) Therapeutics Co. Ltd.
―
Mabpharm Limited
―
Sirnaomics Ltd.
―
SinoMab Bioscience Ltd.
―
Transcenta Holding Limited
―
Options Prices
Currently, No data available
---